Latest Funding Agreements News

American West Metals (ASX: AW1) has raised A$10 million through an oversubscribed institutional placement to fast-track exploration at its West Desert and Storm Copper projects, focusing on high-demand critical metals.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

88 Energy has amended its Participation Agreement with Burgundy Xploration, extending funding milestones to align with Burgundy’s US IPO process while securing US$400,000 in near-term payments and enhanced lease security. The Franklin Bluffs-1H well spud is now expected in Q1 2027, slightly delayed but underpinned by strong capital commitment.

Nelson Resources has obtained key mining leases at its Yarri Gold Project, unlocking expansion potential in high-grade zones and securing up to A$10 million in funding from MEGA Resources to fast-track development.

Riversgold Limited has reported standout assay results from 31 drill holes at its Northern Zone Gold Project, including a spectacular 71 g/t gold intercept. The campaign expands the shallow gold mineralisation footprint, supporting imminent mining lease conversion and a funding agreement with MEGA Resources.

Minerals 260 secures Foreign Investment Review Board approval, enabling Franco-Nevada to complete a $220 million funding package that accelerates development of the Bullabulling Gold Project.

Anax Metals has successfully raised $10 million through a two-tranche placement, strengthening its financial position ahead of critical funding and development milestones for the Whim Creek Copper Project.

Element 25 Limited is advancing its Butcherbird Manganese Mine expansion and developing a US-based battery-grade manganese refinery, supported by major funding and strategic partnerships.

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.

Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.

Emyria Limited has reported a significant 136% increase in revenue to $1.55 million for the half-year ended December 2025, driven by its expanding Empax clinic network and insurer-funded treatments across Australia. Despite this growth, the company posted a $2.37 million net loss, reflecting investments in scaling operations and infrastructure.

Minerals 260 has locked in a $220 million strategic funding deal with Franco-Nevada, boosting development and de-risking the Bullabulling Gold Project in Western Australia. This marks Franco-Nevada’s largest Australian investment to date.